IN BRIEF: Hemogenyx expands trial to include paediatric patients

14th May 2025 14:28

Hemogenyx Pharmaceuticals PLC - London-headquartered biopharmaceutical company focused on treatments for blood diseases - Says it has filed, with the US Food & Drug Administration, an amendment to the clinical protocol for its ongoing phase 1 clinical trial of HG-CT-1 to include paediatric patients with relapsed/refractory acute myeloid leukemia, or R/R AML. CAR-T therapy HG-CT-1 is currently undergoing clinical trials to treat R/R AML in adults. Company says the amendment "seeks to expand eligibility for the trial beyond adult patients to include children and adolescents with R/R AML, an aggressive disease with limited treatment options and poor prognosis in the relapsed/refractory setting". Adds that expanding eligibility reflects its commitment to broadening the potential impact of HG-CT-1, and to addressing a critical unmet medical need in paediatric oncology.

Chief Executive Officer & Co-Founder Vladislav Sandler comments: "We are pleased to take this important step toward making HG-CT-1 available to paediatric patients who currently have very few therapeutic options. The inclusion of children and adolescents in the trial not only reflects our commitment to addressing urgent medical needs across age groups but also supports the broader potential of HG-CT-1 as a transformative therapy for AML."

Current stock price: 180.30 pence, up 0.7% on Wednesday in London

12-month change: down 71%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Get more news and expert articles direct to your inbox